Nucleoside transporters and immunosuppressive adenosine signaling in the tumor microenvironment: Potential therapeutic opportunities

Pharmacol Ther. 2022 Dec:240:108300. doi: 10.1016/j.pharmthera.2022.108300. Epub 2022 Oct 22.

Abstract

Adenosine compartmentalization has a profound impact on immune cell function by regulating adenosine localization and, therefore, extracellular signaling capabilities, which suppresses immune cell function in the tumor microenvironment. Nucleoside transporters, responsible for the translocation and cellular compartmentalization of hydrophilic adenosine, represent an understudied yet crucial component of adenosine disposition in the tumor microenvironment. In this review article, we will summarize what is known regarding nucleoside transporter's function within the purinome in relation to currently devised points of intervention (i.e., ectonucleotidases, adenosine receptors) for cancer immunotherapy, alterations in nucleoside transporter expression reported in cancer, and potential avenues for targeting of nucleoside transporters for the desired modulation of adenosine compartmentalization and action. Further, we put forward that nucleoside transporters are an unexplored therapeutic opportunity, and modulation of nucleoside transport processes could attenuate the pathogenic buildup of immunosuppressive adenosine in solid tumors, particularly those enriched with nucleoside transport proteins.

Keywords: Adenosine; Drug; Immunosuppression; Nucleoside; Receptor; Signaling; Transporter.

Publication types

  • Review
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adenosine / metabolism
  • Humans
  • Immunosuppressive Agents
  • Neoplasms* / drug therapy
  • Nucleoside Transport Proteins* / metabolism
  • Nucleosides
  • Receptors, Purinergic P1 / metabolism
  • Tumor Microenvironment

Substances

  • Nucleoside Transport Proteins
  • Adenosine
  • Nucleosides
  • Receptors, Purinergic P1
  • Immunosuppressive Agents